PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32738096-7	2020	Mechanistically, butyrate induced small intestinal IL-10 expression and downregulated the claudin-2 expression.	Butyrates	17-25	interleukin 10	Mus musculus	51-56	
33631650-12	2021	Butyrate induced B cell regulation by increasing IL-10-producing B (B10) cells and decreasing IL-17-producing B cells, through the circadian clock genes RAR-related orphan receptor alpha and nuclear receptor subfamily 1 group D member 1.	Butyrates	0-8	interleukin 10	Mus musculus	49-54	
33631650-13	2021	CONCLUSION: The findings of this study imply that butyrate may ameliorate SS via reciprocal regulation of IL-10- and IL-17-producing B cells.	Butyrates	50-58	interleukin 10	Mus musculus	106-111	
32738096-8	2020	Finally, IL-10 neutralization abolished the protective effects of butyrate against hepatic IR injury.	Butyrates	66-74	interleukin 10	Mus musculus	9-14	
30918945-7	2019	Interestingly, butyrate upregulated IL-10 production in T cells both under Th1 and Th17 cell conditions.	Butyrates	15-23	interleukin 10	Mus musculus	36-41	
30918945-8	2019	Furthermore, butyrate induced T-cell B-lymphocyte-induced maturation protein 1 (Blimp1) expression, and deficiency of Blimp1 in T cells impaired the butyrate upregulation of IL-10 production, indicating that butyrate promotes T-cell IL-10 production at least partially through Blimp1.	Butyrates	149-157	interleukin 10	Mus musculus	174-179	
30918945-8	2019	Furthermore, butyrate induced T-cell B-lymphocyte-induced maturation protein 1 (Blimp1) expression, and deficiency of Blimp1 in T cells impaired the butyrate upregulation of IL-10 production, indicating that butyrate promotes T-cell IL-10 production at least partially through Blimp1.	Butyrates	149-157	interleukin 10	Mus musculus	174-179	
30918945-11	2019	CONCLUSIONS: These data indicate that butyrate controls the capacity of T cells in the induction of colitis by differentially regulating Th1 and Th17 cell differentiation and promoting IL-10 production, providing insights into butyrate as a potential therapeutic for the treatment of inflammatory bowel disease.	Butyrates	38-46	interleukin 10	Mus musculus	185-190	
30918945-11	2019	CONCLUSIONS: These data indicate that butyrate controls the capacity of T cells in the induction of colitis by differentially regulating Th1 and Th17 cell differentiation and promoting IL-10 production, providing insights into butyrate as a potential therapeutic for the treatment of inflammatory bowel disease.	Butyrates	227-235	interleukin 10	Mus musculus	185-190	
28802151-5	2017	Butyrate (100muM and 500muM) inhibited pro-inflammatory cytokine production (i.e., IL-8 in COLO205 and TNF-alpha, IL-6 and IL-12 in macrophages) but promoted anti-inflammatory cytokine (i.e., IL-10) production in RAW264.7 cells.	Butyrates	0-8	interleukin 10	Mus musculus	192-197	
30034392-9	2018	Interleukin-10 (IL-10) produced by butyrate-induced expanded Treg cells was critical, as treatment with butyrate did not affect inflammatory arthritis in IL-10-knockout mice.	Butyrates	35-43	interleukin 10	Mus musculus	0-14	
30034392-9	2018	Interleukin-10 (IL-10) produced by butyrate-induced expanded Treg cells was critical, as treatment with butyrate did not affect inflammatory arthritis in IL-10-knockout mice.	Butyrates	35-43	interleukin 10	Mus musculus	16-21	
30034392-9	2018	Interleukin-10 (IL-10) produced by butyrate-induced expanded Treg cells was critical, as treatment with butyrate did not affect inflammatory arthritis in IL-10-knockout mice.	Butyrates	104-112	interleukin 10	Mus musculus	0-14	
30660077-0	2019	Butyrate inhibit collagen-induced arthritis via Treg/IL-10/Th17 axis.	Butyrates	0-8	interleukin 10	Mus musculus	53-58	
30660077-9	2019	Butyrate significantly inhibited expressions of IL-1beta, IL-6 and IL-17A, but promoted the expression of IL-10.	Butyrates	0-8	interleukin 10	Mus musculus	106-111	
28802151-8	2017	The administration of oral butyrate (100mg/kg) significantly improved histological scores in both colitis models, including the IL-10-/- mice.	Butyrates	27-35	interleukin 10	Mus musculus	128-133	
28802151-11	2017	These anti-colitic effects of butyrate were IL-10-independent.	Butyrates	30-38	interleukin 10	Mus musculus	44-49	
23086919-7	2012	Coculture of splenocytes with LPS-stimulated DCs pretreated with or without butyrate was performed and showed a significant induction of IL-17 and IL-10.	Butyrates	76-84	interleukin 10	Mus musculus	147-152	
28861518-6	2017	Expression of Il10, Tgfbeta, and Muc2 was elevated in noninfected mice administered butyrate in comparison to mice not administered butyrate.	Butyrates	84-92	interleukin 10	Mus musculus	14-18	
27943364-0	2017	The Inflammation Induced by Lipopolysaccharide can be Mitigated by Short-chain Fatty Acid, Butyrate, through Upregulation of IL-10 in Septic Shock.	Butyrates	91-99	interleukin 10	Mus musculus	125-130	
27943364-9	2017	However, when detecting the anti-inflammatory factors, a significant increase in IL-10, but not TGF-beta or LXT4, was shown in butyrate-pretreated group.	Butyrates	127-135	interleukin 10	Mus musculus	81-86	
27943364-10	2017	Pretreatment of RAW 264.7 cells with butyrate led to downregulation of LPS-induced pro-inflammatory mediators, IL-6 and IL-1beta, but did not affect the level of TNF-alpha, and increased IL-10 (P < 0.01).	Butyrates	37-45	interleukin 10	Mus musculus	187-192	
26944415-6	2016	Furthermore, CD4(+)Foxp3(+) Tregs in the LP and concentrations of total SCFA, acetate, propionate, and butyrate in the caecum were markedly increased after MF feeding in IL-10(-/-) mice.	Butyrates	103-111	interleukin 10	Mus musculus	170-175